South Korea
· Delayed Price · Currency is KRW Chong Kun Dang Pharmaceutical Statistics
Total Valuation
Chong Kun Dang Pharmaceutical has a market cap or net worth of KRW 1.44 trillion. The enterprise value is 1.32 trillion.
| Market Cap | 1.44T |
| Enterprise Value | 1.32T |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Chong Kun Dang Pharmaceutical has 12.63 million shares outstanding. The number of shares has decreased by -0.51% in one year.
| Shares Outstanding | 12.63M |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.00% |
| Owned by Institutions (%) | 22.88% |
| Float | 7.51M |
Valuation Ratios
The trailing PE ratio is 6.81.
| PE Ratio | 6.81 |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| PB Ratio | 1.65 |
| P/FCF Ratio | 6.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.81, with an EV/FCF ratio of 6.02.
| EV / Earnings | 6.21 |
| EV / Sales | 0.79 |
| EV / EBITDA | 4.81 |
| EV / EBIT | 5.57 |
| EV / FCF | 6.02 |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.99 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.79 |
| Debt / FCF | 0.98 |
| Interest Coverage | 26.91 |
Financial Efficiency
Return on equity (ROE) is 27.69% and return on invested capital (ROIC) is 14.70%.
| Return on Equity (ROE) | 27.69% |
| Return on Assets (ROA) | 11.15% |
| Return on Capital (ROIC) | 14.70% |
| Revenue Per Employee | 729.01M |
| Profits Per Employee | 93.08M |
| Employee Count | 2,286 |
| Asset Turnover | 1.26 |
| Inventory Turnover | 3.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.23% in the last 52 weeks. The beta is 0.83, so Chong Kun Dang Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +18.23% |
| 50-Day Moving Average | 116,866.00 |
| 200-Day Moving Average | 110,346.71 |
| Relative Strength Index (RSI) | 46.13 |
| Average Volume (20 Days) | 38,741 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chong Kun Dang Pharmaceutical had revenue of KRW 1.67 trillion and earned 212.79 billion in profits. Earnings per share was 16,762.86.
| Revenue | 1.67T |
| Gross Profit | 655.60B |
| Operating Income | 236.78B |
| Pretax Income | 237.53B |
| Net Income | 212.79B |
| EBITDA | 274.31B |
| EBIT | 236.78B |
| Earnings Per Share (EPS) | 16,762.86 |
Balance Sheet
The company has 339.39 billion in cash and 216.08 billion in debt, giving a net cash position of 123.31 billion or 9,763.44 per share.
| Cash & Cash Equivalents | 339.39B |
| Total Debt | 216.08B |
| Net Cash | 123.31B |
| Net Cash Per Share | 9,763.44 |
| Equity (Book Value) | 875.04B |
| Book Value Per Share | 69,074.43 |
| Working Capital | 493.80B |
Cash Flow
In the last 12 months, operating cash flow was 257.82 billion and capital expenditures -38.18 billion, giving a free cash flow of 219.64 billion.
| Operating Cash Flow | 257.82B |
| Capital Expenditures | -38.18B |
| Free Cash Flow | 219.64B |
| FCF Per Share | 17,391.66 |
Margins
Gross margin is 39.34%, with operating and profit margins of 14.21% and 12.77%.
| Gross Margin | 39.34% |
| Operating Margin | 14.21% |
| Pretax Margin | 14.25% |
| Profit Margin | 12.77% |
| EBITDA Margin | 16.46% |
| EBIT Margin | 14.21% |
| FCF Margin | 13.18% |
Dividends & Yields
This stock pays an annual dividend of 1,047.62, which amounts to a dividend yield of 0.93%.
| Dividend Per Share | 1,047.62 |
| Dividend Yield | 0.93% |
| Dividend Growth (YoY) | 15.50% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 6.26% |
| Buyback Yield | 0.51% |
| Shareholder Yield | 1.44% |
| Earnings Yield | 14.68% |
| FCF Yield | 15.23% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Chong Kun Dang Pharmaceutical has an Altman Z-Score of 3.99.
| Altman Z-Score | 3.99 |
| Piotroski F-Score | n/a |